Evofem Biosciences, Inc. (EVFM)
USD 0.01
(-6.25%)
USD 0.01
(-6.25%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 43.37 Million USD | -39.02% |
| 2022 | 71.12 Million USD | -38.51% |
| 2021 | 115.68 Million USD | 34.61% |
| 2020 | 85.94 Million USD | 43524.37% |
| 2019 | 197 Thousand USD | -95.09% |
| 2018 | 4.01 Million USD | 0.0% |
| 2017 | - USD | 0.0% |
| 2016 | - USD | -100.0% |
| 2015 | 9.96 Million USD | 2.26% |
| 2014 | 9.74 Million USD | 4603.63% |
| 2013 | 207.09 Thousand USD | -67.03% |
| 2012 | 628.14 Thousand USD | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 42.41 Million USD | -2.22% |
| 2024 Q2 | 43.39 Million USD | 2.32% |
| 2023 FY | 43.37 Million USD | -39.02% |
| 2023 Q2 | 43.19 Million USD | -22.16% |
| 2023 Q3 | 41.23 Million USD | -4.55% |
| 2023 Q4 | 43.37 Million USD | 5.2% |
| 2023 Q1 | 55.49 Million USD | -21.98% |
| 2022 Q4 | 71.12 Million USD | -15.07% |
| 2022 Q2 | 125.73 Million USD | 4.47% |
| 2022 Q1 | 120.36 Million USD | 4.05% |
| 2022 FY | 71.12 Million USD | -38.51% |
| 2022 Q3 | 83.74 Million USD | -33.4% |
| 2021 Q2 | 78.14 Million USD | -10.15% |
| 2021 Q1 | 86.97 Million USD | 1.2% |
| 2021 Q3 | 102.61 Million USD | 31.31% |
| 2021 Q4 | 115.68 Million USD | 12.74% |
| 2021 FY | 115.68 Million USD | 34.61% |
| 2020 FY | 85.94 Million USD | 43524.37% |
| 2020 Q3 | 56.2 Million USD | 13.43% |
| 2020 Q4 | 85.94 Million USD | 52.9% |
| 2020 Q2 | 49.55 Million USD | 18529.7% |
| 2020 Q1 | 266 Thousand USD | 35.03% |
| 2019 Q4 | 197 Thousand USD | -48.43% |
| 2019 Q2 | 580 Thousand USD | -87.87% |
| 2019 Q1 | 4.78 Million USD | 19.25% |
| 2019 FY | 197 Thousand USD | -95.09% |
| 2019 Q3 | 382 Thousand USD | -34.14% |
| 2018 Q2 | - USD | 0.0% |
| 2018 Q3 | - USD | 0.0% |
| 2018 Q4 | 4.01 Million USD | 0.0% |
| 2018 FY | 4.01 Million USD | 0.0% |
| 2018 Q1 | - USD | 0.0% |
| 2017 FY | - USD | 0.0% |
| 2017 Q4 | - USD | 0.0% |
| 2017 Q3 | - USD | 0.0% |
| 2017 Q2 | - USD | 0.0% |
| 2017 Q1 | - USD | 0.0% |
| 2016 FY | - USD | -100.0% |
| 2016 Q1 | 3.93 Million USD | -60.45% |
| 2016 Q4 | - USD | 0.0% |
| 2016 Q3 | - USD | -100.0% |
| 2016 Q2 | 4 Million USD | 1.54% |
| 2015 Q1 | 9.78 Million USD | 0.48% |
| 2015 Q3 | 9.9 Million USD | 0.59% |
| 2015 Q4 | 9.96 Million USD | 0.59% |
| 2015 FY | 9.96 Million USD | 2.26% |
| 2015 Q2 | 9.84 Million USD | 0.59% |
| 2014 Q3 | 3.89 Million USD | 0.0% |
| 2014 FY | 9.74 Million USD | 4603.63% |
| 2014 Q4 | 9.74 Million USD | 149.78% |
| 2013 FY | 207.09 Thousand USD | -67.03% |
| 2013 Q4 | 207.09 Thousand USD | 0.0% |
| 2012 FY | 628.14 Thousand USD | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | -5.267% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -952.243% |
| SQZ Biotechnologies Company | 27.47 Million USD | -57.886% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | -45.708% |
| Mesoblast Limited | 118.7 Million USD | 63.46% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -4473.903% |
| Genus plc | 233.1 Million USD | 81.393% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -1380.111% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -3128.157% |
| Marizyme, Inc. | 18.71 Million USD | -131.724% |
| ContraFect Corporation | 2.88 Million USD | -1405.484% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -5683.067% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -31912.665% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -2898.854% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -1764.739% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -666.53% |
| MultiCell Technologies, Inc. | 202.58 USD | -21410207.039% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 24.554% |
| EV Biologics, Inc. | 1.49 Million USD | -2801.687% |
| Q BioMed Inc. | 4.1 Million USD | -955.309% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | -31.032% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -6783.762% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -3430.965% |
| Biomind Labs Inc. | 735.54 Thousand USD | -5796.74% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Pharming Group N.V. | 171.54 Million USD | 74.716% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -233.716% |
| Skye Bioscience, Inc. | 4.61 Million USD | -839.772% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -4783.995% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -30548.398% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -638.755% |
| IMV Inc. | 28.88 Million USD | -50.163% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -168541.86% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -1820.535% |
| GB Sciences, Inc. | 1.75 Million USD | -2365.346% |
| Alpha Cognition Inc. | 1.22 Million USD | -3454.08% |
| HST Global, Inc. | 98.31 Thousand USD | -44014.566% |
| CSL Limited | 12.18 Billion USD | 99.644% |
| Halberd Corporation | 150 Thousand USD | -28815.333% |
| Enzolytics Inc. | 996.33 Thousand USD | -4253.242% |
| Resverlogix Corp. | 6.49 Million USD | -568.202% |
| Affymax, Inc. | - USD | -Infinity% |
| SYBLEU INC | 477.5 Thousand USD | -8983.351% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -16869.623% |
| argenx SE | 20 Million USD | -116.865% |
| MetaStat, Inc. | - USD | -Infinity% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 4.8% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -1501.246% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -424085.819% |
| Genscript Biotech Corporation | 417.73 Million USD | 89.617% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -21519.911% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -1708.924% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -18816.137% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 35.879% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -1333.254% |
| Adynxx, Inc. | - USD | -Infinity% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -11957.769% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Capstone Therapeutics Corp. | 20.32 Million USD | -113.366% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -29077.15% |
| BioStem Technologies, Inc. | 4.71 Million USD | -820.594% |
| ONE Bio Corp. | 19.71 Million USD | -120.0% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -17236.579% |
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -17338.485% |
| Agentix Corp. | 50 Thousand USD | -86646.0% |
| LadRx Corporation | 33.6 Thousand USD | -128963.263% |
| Cell Source, Inc. | 9.25 Million USD | -368.686% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5635.622% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -5635.622% |
| NovAccess Global Inc. | 2.19 Million USD | -1871.608% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -513.236% |
| Itoco Inc. | 228.37 Thousand USD | -18891.842% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -20458.36% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -770.419% |
| Kadimastem Ltd | 891.22 Thousand USD | -4766.667% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -10693.358% |
| CytoDyn Inc. | 30.07 Million USD | -44.211% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| Mobile Lads Corp. | 484.28 Thousand USD | -8856.108% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Qrons Inc. | 351.84 Thousand USD | -12227.233% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -454.645% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -35306.531% |
| Rebus Holdings, Inc. | 310 Thousand USD | -13891.29% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -815.954% |
| International Stem Cell Corporation | 4.17 Million USD | -938.128% |
| Bioxytran, Inc. | 1.92 Million USD | -2153.143% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -69393.535% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -1888.766% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -421.561% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -405.218% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -2688.402% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -16083.955% |
| Neutra Corp. | 54.15 Thousand USD | -79989.002% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -2270.109% |
| PureTech Health plc | 25.51 Million USD | -70.01% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -3442.892% |
| IXICO plc | 472.02 Thousand USD | -9088.747% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -179.808% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 30.339% |
| CSL Limited | 12.18 Billion USD | 99.644% |
| Cellectis S.A. | 92.77 Million USD | 53.25% |